Search Within

Advanced Practice Providers

  1. "Weinberg Fellows"
Formats
  1. Meeting Abstract (49)
  2. Journal Article (30)
  3. Editorial (2)
  4. Research Letter (2)
  5. Review (2)
  6. Correspondence (1)
Groups
  1. Department of Medicine (86)
  2. Weinberg Fellows (86)
  3. Hematologic Malignancies, Division of (60)
  4. Center for Hematologic Malignancies (57)
  5. Nursing (57)
  6. Epidemiology and Biostatistics (55)

More Groups

People
  1. Ahmet Dogan (18)
  2. Gunjan Shah (18)
  3. Alison Moskowitz (17)
  4. Andrew Zelenetz (17)
  5. Colette Owens (17)
  6. Miguel-Angel Perales (17)

More People

Years
  1. 2025 (2)
  2. 2024 (10)
  3. 2023 (12)
  4. 2022 (8)
  5. 2021 (17)
  6. 2020 (9)

More Years

Publications
  1. Blood (24)
  2. Journal of Clinical Oncology (12)
  3. Biology of Blood and Marrow Transplantation (4)
  4. Leukemia and Lymphoma (4)
  5. Cancer Research (3)
  6. Hematological Oncology (3)

More Publications

Publishers
  1. American Society of Hematology (26)
  2. American Society of Clinical Oncology (17)
  3. Elsevier Inc. (7)
  4. American Association for Cancer Research (5)
  5. Elsevier Science, Inc. (5)
  6. Nature Publishing Group (5)

More Publishers

Results (86)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The effect of neutropenia and filgrastim (G-CSF) on cancer patients with coronavirus disease 2019 (COVID-19) infection
    Journal Article

    Zhang, A. W.; Morjaria, S.; Kaltsas, A.; Hohl, T. M.; Parameswaran, R.; Patel, D.; Zhou, W.; Predmore, J.; Perez-Johnston, R.; Jee, J.; more...
    Clinical Infectious Diseases (2022)

    Fulltext@MSK | Save
  • Atypical pathogens presenting with pulmonary consolidations detected by cell-free DNA next-generation sequencing in patients with hematologic malignancies
    Review

    Caldararo, M.; Algazaq, J.; Schmidt, E.; Joanow, A.; Mariano, A.; Predmore, J.; Politikos, I.; Cho, C.; Stein, E. M.; Wen, X.; more...
    Infectious Diseases in Clinical Practice (2022)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Timing and immune status after cellular therapies predict response to COVID-19 vaccines
    Meeting Abstract

    Tamari, R.; Politikos, I.; Knorr, D.; Vardhana, S.; Young, J.; Marcello, L.; Doddi, S.; Devlin, S. M.; Ramanathan, L.; Pessin, M. S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen)
    Meeting Abstract

    Kumar, A.; Soumerai, J. D.; Abramson, J. S.; Batlevi, C. L.; Chadha, P.; Dogan, A.; Falchi, L.; Flaherty, K.; Friedman, C.; Grieve, C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Iomab with adoptive cellular therapy (Iomab-ACT): A pilot study of 131-I apamistamab followed by CD19-targeted car T-cell therapy for patients with relapsed or refractory B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma
    Meeting Abstract

    Geyer, M. B.; Cadzin, B.; Halton, E.; Kane, P.; Senechal, B.; Geoghegan, E. M.; Reddy, V.; Berger, M. S.; Ludwig, D.; Pandit-Taskar, N.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas
    Journal Article

    Moskowitz, A. J.; Ghione, P.; Jacobsen, E.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Vardhana, S.; Ganesan, N.; Hancock, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant
    Journal Article

    Bewersdorf, J. P.; Derkach, A.; Gowda, L.; Menghrajani, K.; DeWolf, S.; Ruiz, J. D.; Ponce, D. M.; Shaffer, B. C.; Tamari, R.; Young, J. W.; more...
    Leukemia and Lymphoma (2021)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schòˆder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Predictors of humoral response to SARS-CoV-2 vaccination after hematopoietic cell transplantation and CAR T-cell therapy
    Journal Article

    Tamari, R.; Politikos, I.; Knorr, D. A.; Vardhana, S. A.; Young, J. C.; Marcello, L. T.; Doddi, S.; Devlin, S. M.; Ramanathan, L. V.; Pessin, M. S.; more...
    Blood Cancer Discovery (2021)

    Fulltext@MSK | Save